[Long-term therapy with nucleoside analog entecavir (baraclude) in patients with chronic hepatitis B]. 2011

Małgorzata Pawłowska, and Waldemar Halota
Katedra Chorób Zakaźnych i Hepatologii Collegium Medicum im. L. Rydygiera w Bydgoszczy Uniwersytet Mikolaja Kopernika w Toruniu. kikchzak@cm.umk.pl

Complications of HBV infection include cirrhosis and hepatocellular carcinoma (HCC), which together cause over 500.000 deaths annually. There are many risk factors of disease progression as: age, sex, comorbidities, family history, HBV genotypes, viral load, HBeAg status, disease stage etc. Chronic hepatitis B patients with high viral load have the highest risk of progressing to these life-threatening complications. The management of chronic hepatitis B currently rests with long-term therapy using nucleoside analogs. The goal of this therapy is sustained HBV DNA suppression, improving quality of life and preventing progression of the disease to cirrhosis, end-stage liver disease, HCC and death. The major limitations of long-term therapy is antiviral resistance. Entecavir provides sustained viral suppression and histological benefit with minimal resistance during long-term treatment of chronic hepatitis B, it is well-tolerable and has good safety profile, simple dosing and simple monitoring requirements.

UI MeSH Term Description Entries
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D008297 Male Males
D005260 Female Females
D006147 Guanine
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Małgorzata Pawłowska, and Waldemar Halota
June 2005, The Medical letter on drugs and therapeutics,
Małgorzata Pawłowska, and Waldemar Halota
February 2017, Prescrire international,
Małgorzata Pawłowska, and Waldemar Halota
June 2010, Journal of hepatology,
Małgorzata Pawłowska, and Waldemar Halota
October 2008, Expert review of anti-infective therapy,
Małgorzata Pawłowska, and Waldemar Halota
May 2011, Hepatology research : the official journal of the Japan Society of Hepatology,
Małgorzata Pawłowska, and Waldemar Halota
November 2016, Journal of gastroenterology and hepatology,
Małgorzata Pawłowska, and Waldemar Halota
September 2021, BMC infectious diseases,
Małgorzata Pawłowska, and Waldemar Halota
August 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Małgorzata Pawłowska, and Waldemar Halota
December 2006, Pharmacotherapy,
Małgorzata Pawłowska, and Waldemar Halota
November 2012, Scandinavian journal of gastroenterology,
Copied contents to your clipboard!